Kukje Pharma Co., Ltd. Stock

Equities

A002720

KR7002720001

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4,940 KRW -1.10% Intraday chart for Kukje Pharma Co., Ltd. +1.13% -16.55%
Sales 2022 127B 92.03M Sales 2023 135B 98.42M Capitalization 120B 87.16M
Net income 2022 3.56B 2.59M Net income 2023 -8.42B -6.12M EV / Sales 2022 1.02 x
Net Debt 2022 23.04B 16.75M Net Debt 2023 20.03B 14.56M EV / Sales 2023 1.03 x
P/E ratio 2022
29.9 x
P/E ratio 2023
-14.2 x
Employees 259
Yield 2022 *
-
Yield 2023
-
Free-Float 57.66%
More Fundamentals * Assessed data
Dynamic Chart
Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
OncoPep, Inc. announced that it has received $11 million in funding from TERA SCIENCE Co.,LTD, Crystal Bioscience Inc., Kukje Pharma Co., Ltd. CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Coronavirus infects Asia stocks with exposure to China RE
ASX 200 : Coronavirus infects Asia stocks with exposure to China RE
Tranche Update on Kukje Pharmaceutical Industrial Co. Ltd.'s Equity Buyback Plan announced on November 2, 2016. CI
Kukje Pharmaceutical Industrial Co. Ltd.'s Equity Buyback announced on November 2, 2016, has closed with 300,000 shares, representing 1.81% for KRW 1,371.73 million. CI
Kukje Pharmaceutical Industrial Co. Ltd. authorizes a Buyback Plan. CI
More news
1 day-1.10%
1 week+1.13%
Current month-16.41%
1 month-22.20%
3 months-0.10%
6 months-7.84%
Current year-16.55%
More quotes
1 week
4 880.00
Extreme 4880
5 120.00
1 month
4 795.00
Extreme 4795
6 410.00
Current year
4 365.00
Extreme 4365
8 120.00
1 year
3 530.00
Extreme 3530
8 120.00
3 years
3 530.00
Extreme 3530
8 589.57
5 years
2 980.24
Extreme 2980.2397
14 987.58
10 years
1 506.78
Extreme 1506.7811
14 987.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 09-03-31
Chief Executive Officer 64 85-02-28
Chief Executive Officer 81 04-12-31
Members of the board TitleAgeSince
Director/Board Member 44 -
Chief Executive Officer 81 04-12-31
Chief Executive Officer 64 85-02-28
More insiders
Date Price Change Volume
24-04-26 4,940 -1.10% 172,289
24-04-25 4,995 -1.48% 136,358
24-04-24 5,070 +1.50% 154,985
24-04-23 4,995 -0.70% 195,013
24-04-22 5,030 +2.97% 332,292

End-of-day quote Korea S.E., April 25, 2024

More quotes
Kukje Pharma Co., Ltd, formerly Kukje Pharma Ind. Co., Ltd, is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products are finished products, such as antibiotics, other antibiotics for injection, antifungal and antiviral agents, agents for gastrointestinal tract and liver, muscle relaxants, anti-osteoporotics, corticosteroids, agents for cardiovascular and endocrine systems, ophthalmic agents, remedies for central nervous system (CNS) disorders, remedies for urinary systems, antihistamines, antitussives, cough and cold remedies, non-steroidal anti inflammatory drugs (NSAIDs), antitussive, cough and cold remedies, as well as other over-the-counter (OTC) drugs. It also provides raw materials, such as ceftriaxone sodium sterile, cefuroxime axetil, ceftezole sodium sterile, cefminox sodium sterile, cefuroxime sodium sterile and others.
More about the company
  1. Stock Market
  2. Equities
  3. A002720 Stock